Triptorelin

Generic Name: Triptorelin

Brand Names: Decapeptyl, Trelstar, Triptodur

Drug Type: Small Molecule

Chemical Formula: C_₆₄H_₈₂N_₁₈O_₁₃

CAS Number: 57773-63-4

Unique Ingredient Identifier: 9081Y98W2V

Background: Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.

Indication: Triptorelin is indicated for the palliative treatment of advanced prostate cancer.

Associated Conditions: Advanced Prostate Cancer

Associated Therapies: Controlled ovarian hyperstimulation therapy

Clinical Trials

Study on Human Bioequivalence of Triprerelin Acetate for Injection

Phase 1

Recruiting

Conditions: Prostate Cancer (CRPC)

Interventions: Drug: Triprorelin for injection
Drug: Diphereline

First Posted Date: 2024-11-11

Last Posted Date: 2024-11-11

Lead Sponsor: The Affiliated Hospital of Qingdao University

Target Recruit Count: 120

Registration Number: NCT06683066

Locations: 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China

Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst Transfer

Not Applicable

Completed

Conditions: Adenomyosis

Interventions: Device: levonorgestrel-releasing intrauterine system
Drug: Triptorelin
Procedure: frozen embryo transfer

First Posted Date: 2024-09-03

Last Posted Date: 2024-09-03

Lead Sponsor: Zagazig University

Target Recruit Count: 184

Registration Number: NCT06581679

Locations: 🇪🇬
Zagazig university, Zagazig, Ash Sharqia Governorate, Egypt

Effect GnRH Agonist Administration in Endometriosis Cyst Patients

Phase 3

Recruiting

Conditions: Endometriosis

Interventions: Drug: Triptorelin Embonate

First Posted Date: 2024-07-29

Last Posted Date: 2024-11-25

Lead Sponsor: Rumah Sakit Pusat Angkatan Darat Gatot Soebroto

Target Recruit Count: 32

Registration Number: NCT06525155

Locations: 🇮🇩
Department of Obstetrics and Gynecology Central Army Hospital Gatot Soebroto, Jakarta, Indonesia

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

Phase 3

Recruiting

Conditions: Malignant Solid Neoplasm
Hematopoietic and Lymphatic System Neoplasm

Interventions: Other: Best Practice
Other: Electronic Health Record Review
Procedure: Biospecimen Collection
Other: Survey Administration
Drug: Triptorelin Pamoate

First Posted Date: 2024-07-22

Last Posted Date: 2025-03-19

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 60

Registration Number: NCT06513962

Locations: 🇺🇸
Mercy Hospital Joplin, Joplin, Missouri, United States
🇺🇸
Lake Regional Hospital, Osage Beach, Missouri, United States
🇺🇸
Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States

and more 77 locations

Efficacy, Metabolism and BMD of the 3-month TP Compared to the 1-month TP in ICPP

Phase 4

Not yet recruiting

Conditions: Central Precocious Puberty

Interventions: Drug: Triptorelin pamoate（15mg）
Drug: Triptorelin acetate （3.75mg）

First Posted Date: 2024-07-05

Last Posted Date: 2024-07-05

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 134

Registration Number: NCT06487143

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

Recruiting

Conditions: Prostate Cancer
Hormone Sensitive Prostate Cancer
Metastatic Tumor

Interventions: Radiation: radiotherapy
Drug: Docetaxel
Drug: Apalutamide Oral Tablet
Drug: Darolutamide Oral Tablet
Drug: Enzalutamide Oral Tablet
Drug: Abiraterone acetate tablets
Drug: Triptorelin

First Posted Date: 2024-06-25

Last Posted Date: 2024-06-25

Lead Sponsor: Santa Chiara Hospital

Target Recruit Count: 3000

Registration Number: NCT06473259

Locations: 🇮🇹
Azienda Ospedaliera San Luigi, Orbassano, Torino, Italy
🇮🇹
Istituto Oncologico Veneto, Padova, Italy
🇮🇹
Santa Chiara Hospital, Trento, Italy

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial

Phase 2

Recruiting

Conditions: Recurrent Castration-Sensitive Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8
Recurrent Prostate Cancer
Castration-resistant Prostate Cancer

Interventions: Drug: Abiraterone
Drug: Apalutamide
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Drug: Darolutamide
Drug: Degarelix
Other: Questionnaire Administration
Drug: Enzalutamide
Radiation: Stereotactic Body Radiation Therapy
Drug: Goserelin
Drug: Histrelin
Drug: Leuprolide
Procedure: Magnetic Resonance Imaging
Other: Patient Observation
Procedure: Positron Emission Tomography
Drug: Prednisone
Drug: Relugolix
Drug: Triptorelin

First Posted Date: 2024-04-23

Last Posted Date: 2025-05-15

Lead Sponsor: Mayo Clinic

Target Recruit Count: 220

Registration Number: NCT06378866

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Darolutamide matched placebo
Drug: Darolutamide
Radiation: Radiotherapy
Drug: Zoladex 3.6Mg Implant
Drug: Zoladex LA
Drug: Decapeptyl sustained release 22.5 mg
Drug: Decapeptyl sustained release 11.25 mg
Drug: Depo-Eligard 45 mg
Drug: Depo-Eligard 22.5 mg
Drug: Depo-Eligard 7.5 mg
Drug: Firmagon 120 MG Injection
Drug: Firmagon 80 MG Injection
Drug: Docetaxel

First Posted Date: 2024-02-28

Last Posted Date: 2024-02-28

Lead Sponsor: Cancer Research Antwerp

Target Recruit Count: 493

Registration Number: NCT06282588

Locations: 🇧🇪
AZ Groeninge, Kortrijk, Belgium
🇧🇪
GZA Sint-Augustinus, Wilrijk, Antwerp, Belgium
🇧🇪
OLVZ Aalst, Aalst, Belgium

and more 8 locations

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)

Phase 3

Recruiting

Conditions: Central Precocious Puberty

Interventions: Drug: Debio 4326

First Posted Date: 2023-11-13

Last Posted Date: 2025-05-14

Lead Sponsor: Debiopharm International SA

Target Recruit Count: 56

Registration Number: NCT06129539

Locations: 🇧🇷
Hospital Universitario Walter Cantidio, Fortaleza, Brazil
🇧🇷
Clínica de Endocrinologia e Metabologia Ltda, Lago Sul, Brazil
🇨🇱
ENDOMET, Antofagasta, Chile

and more 41 locations

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

Phase 2

Recruiting

Conditions: Premenopausal Breast Cancer
HER2-negative Breast Cancer
Breast Cancer
Hormone Receptor Positive Tumor

Interventions: Drug: Elacestrant
Drug: Triptorelin

First Posted Date: 2023-08-08

Last Posted Date: 2024-02-13

Lead Sponsor: SOLTI Breast Cancer Research Group

Target Recruit Count: 48

Registration Number: NCT05982093

Locations: 🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Spain
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇪🇸
Complejo Hospitalario San Pedro de Alcántara, Cáceres, Spain

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy